Total Funding
65
50
Total FundingPost-IPO Equity raised
Growth Score
-16 pts
Heat Score
-23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
17490
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
- Rene Russo: Chief Executive Officer
- Martin Huber: PresidentPast Role: Mersana Therapeutics, President & Chief Executive Officer
About the Company
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and
restricts their activity to the tumor to minimize peripheral side effects.
